£1.3 million Iraq Order

RNS Number : 9080N
Inspiration Healthcare Group PLC
07 June 2022
 

 

 

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

 

£1.3 million Iraq Order

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that it has received an order worth £1.3 million for the supply of SLE ventilators and Viomedex consumables to Iraq. Part of the order has already been shipped after an initial payment was received in March 2022 and the remainder of the order is expected to be dispatched within the next few months.

The SLE ventilators are high-specification, sophisticated infant ventilators offering a range of conventional modes with additional options for non-invasive ventilation (NIV), high frequency oscillation ventilation (HFOV) and high flow oxygen therapy.  They are used extensively in Neonatal Intensive Care Units around the world to treat premature and sick babies.

Neil Campbell, Chief Executive Officer, commented: "We are delighted to announce this sizeable order which again demonstrates the expansion of our operations across new international markets and also the cross selling opportunities which continue to be realised within the enlarged group."

  

Enquiries:

 

Inspiration Healthcare Group plc

Neil Campbell, Chief Executive Officer

Jon Ballard, Chief Financial Officer

Tel: +44 (0)330 175 0000  

Cadogan PR 

Alex Walters

alex.walters@cadoganpr.com

Tel: 07771 713608

 

About Inspiration Healthcare Group

 

www.inspirationhealthcaregroup.plc.uk

 

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

 

The Group currently consists of three companies: Inspiration Healthcare Ltd, SLE Ltd and Viomedex Ltd and under these brands the Group sells neonatal intensive care and operating theatre equipment around the work through a network of distributors into over 75 countries.  Products range from highly sophisticated capital equipment through to single use disposables all that can help improve outcomes of extremely sick patients.

 

In the UK and Ireland the Group offers direct sales for most of its products supported by Technical Service offering on site and return to base repair and maintenance along with 24/7 emergency hire of equipment and long term lease arrangements for its own brand products.  The Group also acts as a distributor for 3rd party companies that wish to access the NHS using the Group's sales and service expertise and knowledge of the NHS

 

The Group invests in growth through Research and Development holding numerous patents on its technology and has strong links with academic Key Opinion Leaders around the world and supports clinical research in the field of neonatal intensive care.

 

Further information on Inspiration Healthcare Group plc can be seen at  www.inspirationhealthcaregroup.plc.uk  

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUNSWRUKUNRAR
UK 100

Latest directors dealings